INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio update as at 31 October 2009
Total Net Assets |
£91.9m |
NAV per share |
141.7p |
Share Price |
121.8p |
Total value of unquoted investments |
£18.2m |
Total number of portfolio companies |
58 |
Cash |
9% |
Cash committed and reserved to unquoted investments |
15% |
Portfolio companies with < 1 year of cash |
15% |
Top Ten Holdings
Company Name |
% NAV |
Market Value |
Micromet |
7.92 |
7,276,794 |
Celgene |
6.31 |
5,799,732 |
Amgen |
5.64 |
5,180,290 |
HSBC Sterling Liquid Fund B shares |
4.68 |
4,300,645 |
Gilead Sciences |
4.34 |
3,984,233 |
Prime Rate Sterling Liquidity Class 3 |
3.81 |
3,502,037 |
Alexion Pharmaceuticals |
3.47 |
3,188,462 |
Genzyme |
3.06 |
2,807,900 |
Wright Medical |
2.89 |
2,652,989 |
Halozyme Therapeutics |
2.24 |
2,056,948 |
|
----------- |
-------------- |
Total |
44.36 |
40,750,030 |
Geographical Allocation |
% |
United States |
75 |
Europe |
14 |
Cash |
9 |
Australia |
2 |
|
----------- |
Total |
100 |
Quoted/Unquoted allocation |
% |
Quoted |
71 |
Unquoted |
20 |
Cash |
9 |
|
----------- |
|
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
19 NOVEMBER 2009